Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the effectiveness of omalizumab in a multicentre group of patients with Samter's triad. We retrospectively enrolled eight patients (5 females) with Samter's triad who underwent at least one year of omalizumab therapy. Clinical data, functional parameters and questionnaires for asthma and nasal polyposis control were collected at baseline and follow-up. We observed a significant reduction of moderate-to-severe asthma exacerbations, together with an increase of FEV1 and a reduction of steroids intake. An improvement in asthma control and nasal symptoms was also reported. This multicenter study confirms the effectiveness of omalizumab in patients affected by Samter's triad. Omalizumab may represent a potential therapeutic option for the management of this disease.

A multicenter approach to evaluate omalizumab effectiveness in Samter's triad / Paolo Cameli , Miriana D'Alessandro , Laura Bergantini , Elena Silvestri , Arianna Romaldi , Giacomo Emmi, Paola Parronchi , Elena Bargagli. - In: MONALDI ARCHIVES FOR CHEST DISEASE. - ISSN 1122-0643. - ELETTRONICO. - (2020), pp. 90-93. [10.4081/monaldi.2020.1397]

A multicenter approach to evaluate omalizumab effectiveness in Samter's triad

Elena Silvestri;Arianna Romaldi;Giacomo Emmi;Paola Parronchi;
2020

Abstract

Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the effectiveness of omalizumab in a multicentre group of patients with Samter's triad. We retrospectively enrolled eight patients (5 females) with Samter's triad who underwent at least one year of omalizumab therapy. Clinical data, functional parameters and questionnaires for asthma and nasal polyposis control were collected at baseline and follow-up. We observed a significant reduction of moderate-to-severe asthma exacerbations, together with an increase of FEV1 and a reduction of steroids intake. An improvement in asthma control and nasal symptoms was also reported. This multicenter study confirms the effectiveness of omalizumab in patients affected by Samter's triad. Omalizumab may represent a potential therapeutic option for the management of this disease.
2020
90
93
Goal 3: Good health and well-being for people
Paolo Cameli , Miriana D'Alessandro , Laura Bergantini , Elena Silvestri , Arianna Romaldi , Giacomo Emmi, Paola Parronchi , Elena Bargagli
File in questo prodotto:
File Dimensione Formato  
nmoscato,+MONALDI_2020_3_1397_opt.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 494.27 kB
Formato Adobe PDF
494.27 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1207183
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact